These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2884706)

  • 41. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute ventilatory and gas-exchange effects of a new beta-2 agonist, broxaterol, in asthmatics.
    Tantucci C; Burni B; Dottorini ML; Malerba M; Peccini F; Gurrieri G; Sorbini CA; Grassi V
    Int J Clin Pharmacol Res; 1990; 10(3):183-9. PubMed ID: 1977709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease].
    Ulrik CS
    Ugeskr Laeger; 1996 Jun; 158(25):3604-7. PubMed ID: 8693619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of nifedipine on salbutamol-induced bronchodilation in partially reversible airway obstruction.
    Rolla G; Arossa W; Bucca C; Bugiani M
    Int J Clin Pharmacol Res; 1986; 6(5):409-13. PubMed ID: 3781703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eformoterol versus salbutamol in patients with ROAD.
    Maesen FP
    Br J Clin Pract Suppl; 1995 Sep; 81():8-10. PubMed ID: 8546895
    [No Abstract]   [Full Text] [Related]  

  • 46. Clenbuterol and salbutamol in the symptomatic treatment of patients with reversible airways obstruction.
    Jaffé G; Grimshaw JJ
    Pharmatherapeutica; 1983; 3(7):492-5. PubMed ID: 6366806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of the calcium antagonist tiapamil on pulmonary gas exchange in patients with chronic obstructive pulmonary disease who receive salbutamol.
    Gugger M; Crivelli AM; Galeazzi RL; Bachofen H
    Clin Pharmacol Ther; 1985 Jul; 38(1):96-100. PubMed ID: 4006380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eformoterol versus salbutamol in elderly patients with ROAD.
    Hendrick DJ
    Br J Clin Pract Suppl; 1995 Sep; 81():4-5. PubMed ID: 8546893
    [No Abstract]   [Full Text] [Related]  

  • 49. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
    Taccola M; Bancalari L; Ghignoni G; Paggiaro PL
    Monaldi Arch Chest Dis; 1999 Aug; 54(4):302-6. PubMed ID: 10546469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
    Sprogøe-Jakobsen U; Viktrup L; Davidsen O; Viskum K
    Ugeskr Laeger; 1992 Nov; 154(47):3325-8. PubMed ID: 1361083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is xamoterol safe in chronic airflow obstruction?
    Roberts JA; Challenor VF; Waller DG
    Eur J Clin Pharmacol; 1992; 42(2):147-50. PubMed ID: 1352245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The duration of action of inhaled formoterol dry powder.
    Quebe-Fehling E; Brambilla R; Bromly CL; Fishwick K; Walters EH; Hendrick DJ
    Br J Clin Pract; 1996 Dec; 50(8):446-9. PubMed ID: 9039716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk/benefit ratio of long-term treatment with beta 2-adrenoceptor agonists.
    Ziment I
    Lung; 1990; 168 Suppl():168-76. PubMed ID: 1974672
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ineffectiveness of intravenous beta 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction.
    Malerba M; Boni E; Tantucci C; Filippi B; Romagnoni G; Grassi V
    Respiration; 1996; 63(1):8-16. PubMed ID: 8833987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The protective effect of transdermal broxaterol on exercise-induced bronchoconstriction.
    Robuschi M; Scuri M; Spagnotto S; Gambaro G; Lodola E; Pisati R; Bianco S
    Eur J Clin Pharmacol; 1995; 47(5):465-6. PubMed ID: 7720771
    [No Abstract]   [Full Text] [Related]  

  • 57. Remarks on broxaterol.
    Allegra L
    Respiration; 1989; 55 Suppl 2():41-3. PubMed ID: 2572040
    [No Abstract]   [Full Text] [Related]  

  • 58. Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II.
    Frongia AL; Natera-de Benito D; Ortez C; Alarcón M; Borrás A; Medina J; Vigo M; Padrós N; Moya O; Armas J; Carrera-García L; Expósito-Escudero J; Cuadras D; Bernal S; Martorell L; Colomer J; Nascimento A
    Neuromuscul Disord; 2019 Jul; 29(7):517-524. PubMed ID: 31201046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Daily salbutamol in young patients with SMA type II.
    Pane M; Staccioli S; Messina S; D'Amico A; Pelliccioni M; Mazzone ES; Cuttini M; Alfieri P; Battini R; Main M; Muntoni F; Bertini E; Villanova M; Mercuri E
    Neuromuscul Disord; 2008 Jul; 18(7):536-40. PubMed ID: 18579379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of atopic dermatitis with salbutamol.
    Archer CB; MacDonald DM
    Clin Exp Dermatol; 1987 Sep; 12(5):323-5. PubMed ID: 3446416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.